TECH OUTLOOK 6DECEMBER - 2021TECH OUTLOOKEditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comThe body's immune system helps protect us against disease and infection. It includes a network of cells and organs that help defend the body from "antigens" -- foreign substances such as bacteria, viruses, fungi, harmful toxins and allergens. When antigens are ingested or contact the skin or mucous membranes, they stimulate an immune response: White cells produce antibodies that "coat" the antigens, marking them as targets for other white cells or inactivating them the antigens. The other white cells then attack and destroy the antigens.In most circumstances, the body's natural immune system seems unable to identify cancer as a foreign invader. One reason for this may be that cancer cells aren't external invaders like viruses and bacteria are. Instead, cancer cells are altered versions (mutations) of normal cells and don't produce a unique feature like an antigen that will trigger an immune response. What's more, cancer cells may also suppress immunity, which may contribute to the immune system's failure to recognize cancer cells as foreign invaders. Immunotherapy is based on the concept that immune cells or antibodies that can recognize and kill cancer cells can be produced in the laboratory and then given to patients to treat cancer. While the idea is not new, the speed with which new therapies are being developed and approved to treat an increasing number of cancers has accelerated in the past ten years.In this edition of Pharma Tech Outlook, we present the story of some prominent market leaders such as Equaly and Oblique Therapeutics. This edition brings you some of the most promising organizations specializing in immunotherapy, driving key trends and strategies. Besides, the magazine also offers a combination of thought leadership from subject-matter experts with real-life stories and exclusive insights from CIOs and CXOs. We hope this edition will provide you with the proper assistance in choosing the immunotherapy companies according to your requirements.Let us know your thoughts!Keeping the Promise and Potential of Immunotherapy AliveCopyright © 2021 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.DECEMBER - 2 - 2021, Vol 07 - Issue 05 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com *Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffEditor-in-ChiefStacey SmithVisualizerRonald DonovanAsher BlakeEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul BarberSalesBrian Thomasbrian@pharmatechoutlook.comPhone: 510.556.2402sales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Contact Us:Phone:510.556.2402, Fax:510-894-8405TECH OUTLOOK
< Page 5 | Page 7 >